Oncology Clinical Pathways Marginal Zone Lymphoma

December 2023 - V2.2023







Table of Contents

Presumptive Conditions	3
Marginal Zone Lymphoma – Nodal	4
Marginal Zone Lymphoma – Splenic	5
Marginal Zone Lymphoma – Extranodal	6
Marginal Zone Lymphoma – Relapsed or Refractory	7
Marginal Zone Lymphoma – Molecular Testing Table	8







Marginal Zone Lymphoma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Atomic Veterans – Exposure to Ionizing Radiation

- Lymphomas, other than Hodgkin's disease
- Vietnam Veterans Agent Orange Exposure or Specified Locations
 - Non-Hodgkin's lymphoma

Gulf War and Post 9/11 Veterans

If the patient served on or after Sept. 11, 2001, in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen or if the patient served in the *Southwest Asia theater of operations, or Somalia, on or after Aug. 2, 1990, specific conditions include:

• Lymphoma of any type

* The Southwest Asia theater of operations refers to Iraq, Kuwait, Saudi Arabia, the neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above these locations.

For more information, please visit U.S. Department of Veterans Affairs - Presumptive Disability Benefits (va.gov)








Department

3

<u>Marginal Zone Lymphoma – Nodal</u>



Clinical trial(s) always considered on pathway.

^a Supportive Care and Pre-Therapy Considerations include Hepatitis B serologies prior to starting anti-CD20 antibody therapy (e.g. rituximab); consider HBV DNA if HBsAg or HBcAb positive; consider entecavir if HBsAg or HBcAb positive; COVID and pneumococcal vaccinations recommended; consider VZV/HSV and PJP prophylaxis with any bendamustine-regimen

^b Pathology Workup includes sufficient flow cytometry or IHC workup to exclude other small B-cell lymphomas (e.g. CD5, CD10, CD103, CD200, CD11c, CD25, CD23, BCL2, BCL6, cyclin D1, KI-67, etc.); some molecular testing may be diagnostically useful in certain circumstances

- ^c Stage if clinically limited stage, perform bone marrow biopsy and PET/CT to confirm
- ^d Radiation ISRT recommended

^e Indications for Therapy local symptoms due to nodal disease, reduced organ function due to nodal disease, B-symptoms (fever, weight loss, night sweats), cytopenia attributable to disease (Hgb < 10 g/dL, platelets <100,000/mm3), or an increase in disease tempo


IHC Immunohistochemistry ISRT Involved Site Radiation Therapy Clinical Trial Resources https://clinicaltrials.gov/ and https://lls-forms.careboxhealth.com/?IRC=HCP







Marginal Zone Lymphoma – Splenic




Clinical Trial Resources https://clinicaltrials.gov/ and https://lls-forms.careboxhealth.com/?IRC=HCP







Marginal Zone Lymphoma – Extranodal



Clinical trial(s) always considered on pathway.

* Supportive Care and Pre-Therapy Considerations include Hepatitis B serologies prior to starting anti-CD20 antibody therapy (e.g. rituximab); consider HBV DNA if HBsAg or HBcAb positive; consider entecavir if HBsAg or HBcAb positive; COVID and pneumococcal vaccinations recommended; consider VZV/HSV and PJP prophylaxis with any bendamustine-regimen

^a Pathology Workup includes sufficient flow cytometry or IHC workup to exclude other small B-cell lymphomas (e.g. CD5, CD10, CD103, CD200, CD11c, CD25, CD23, BCL2, BCL6, cyclin D1, KI-67, etc.); some molecular testing may be diagnostically useful in certain circumstances; the presence of t(11;18) is associated with inferior response to H. pylori antibiotic therapy

⁵ Indications for Therapy include cytopenias felt to be due bone marrow involvement by lymphoma; symptomatic adenopathy or splenomegaly, impaired organ function felt to be due to lymphoma

Skin Directed Therapy (appropriate for patients with multifocal low volume disease) examples include palliative radiation therapy (2 Gy x2), intralesional steroids, topical steroids, topical imiquimod

Stage if clinically limited stage, perform bone marrow biopsy and PET/CT to confirm

Local Therapy in certain situations, surgery is used; decision between surgery and radiation therapy should take into consideration the site involved and the risks of either intervention (surgery vs radiation therapy); if the risks of local therapy are excessive, observation may be appropriate, especially in asymptomatic patients

⁹ Complete Lymphoma Response assessment for response to H. pylori therapy for gastric MALT should include evaluation for clearance of H. pylori infection and evaluation for resolution of lymphoma (a complete response may take up to 18 months to be achieved); if there is persistent H. pylori infection, additional antibiotic therapy should be given; the presence of t(11;18) is associated with inferior response to H. pylori antibiotic therapy

^b Clinical Monitoring is recommended after gastric MALT therapy and post-treatment endoscopy demonstrating complete response; routine endoscopy for asymptomatic patients is not recommended; the presence of t(11;18) may require closer monitoring in patients treated with antibiotic therapy


Clinical Trial Resources https://clinicaltrials.gov/ and https://lls-forms.careboxhealth.com/?IRC=HCP







Marginal Zone Lymphoma – Relapsed or Refractory









<u>Marginal Zone Lymphoma – Molecular Testing</u>

Indication	Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
indication	Ligibility	Test Galegory	Test Type	Vendors	IN OF COVERage	opecimen Type
Marginal Zone Lymphoma*	Suspected Nodal Marginal Zone Lymphoma to Assist with Diagnosis	Consider IHC or Flow Cytometry	IHC for CD5, CD10, CD103, CD200, CD11c, CD25, CD23, BCL2, BCL6, cyclin D1, KI-67	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
		Consider FISH		Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
		Consider Targeted Sequencing	MYD88 mutation testing to differentiate from lymphoblastic lymphoma	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
	Suspected Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) to Assist with Diagnosis	Consider IHC or Flow Cytometry	IHC for CD5, CD10, CD103, CD200, CD11c, CD25, CD23, BCL2, BCL6, cyclin D1, KI-67	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
		Consider FISH	FISH for t(11;14) to differentiate from mantle cell lymphoma	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
		Consider Targeted Sequencing	MYD88 mutation testing to differentiate from lymphoplasmacytic lymphoma. Please note that can be found in 5-10% of MALTs.	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
		Consider FISH	FISH for MALT1 break apart, t(1;14), t(3;14), t(14;18), t(11;18)	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
		Consider FISH	Trisomy 3 and trisomy 18. Please note that they may not be specific	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
	Suspected cutaneous Marginal Zone Lymphoma to assist with diagnosis	Consider IHC	IHC for IgM, IgG, IgG4, IgA	Local VA or Locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood

* Routine FISH and molecular testing not required unless required for diagnosis.







Questions?

Contact VHAOncologyPathways@va.gov





